POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer

Pathology International

Volumn 63, Issue 3, 2013, Pages 158-168

  Ishii, Jun ^a,b   Sato, Hanako ^c   Sakaeda, Masashi ^a,b   Shishido Hara, Yukiko ^b   Hiramatsu, Chie ^c   Kamma, Hiroshi ^b   Shimoyamada, Hiroaki ^b   Fujiwara, Masachika ^b   Endo, Tetsuya ^b,d   Aoki, Ichiro ^a   Yazawa, Takuya ^b  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

ASCL1; BRN2; Cell growth; NeuroD1; Neuroendocrine marker; POU domain transcription factor; Small cell lung cancer

Indexed keywords

BIOLOGICAL MARKER; BRN2 PROTEIN; CHROMOGRANIN A; KI 67 ANTIGEN; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; NERVE CELL ADHESION MOLECULE 1; NEUROGENIC DIFFERENTIATION FACTOR; RETROVIRUS VECTOR; SMALL INTERFERING RNA; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR MASH1; TRANSCRIPTION FACTOR POU; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL LINEAGE; CELL POPULATION; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; GENE ACTIVATION; GENE SILENCING; GENETIC TRANSFECTION; GROWTH RETARDATION; HUMAN; HUMAN TISSUE; LUNG SMALL CELL CANCER; MITOSIS; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; TRANSGENE; WESTERN BLOTTING;

APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HOMEODOMAIN PROTEINS; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; NADH DEHYDROGENASE; NEUROSECRETORY SYSTEMS; POU DOMAIN FACTORS; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84875654769     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12042     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Travis WB, Nicholson S, Hirsch FR etal. Small cell carcinoma. In: Travis WB, Brambilla E, Muller-Hermelink HK, Harris CC, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung: Pleura, Thymus, and Heart. Lyon: IARC Press, 2004; 31-34.
3. May M, Siegsmund M, Hammermann F, Loy V, Gunia S. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. Scand J Urol Nephrol 2007; 41: 375-381.
4. Bhattacharjee A, Richards WG, Staunton J etal. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98: 13790-13795.
5. Syder AJ, Karam SM, Mills JC etal. A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype. Proc Natl Acad Sci USA 2004; 101: 4471-4476.
6. Battafarano RJ, Fernandez FG, Ritter J etal. Large cell neuroendocrine carcinoma: An aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005; 130: 166-172.
7. Ball DW, Azzoli CG, Baylin SB etal. Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. Proc Natl Acad Sci USA 1993; 90: 5648-5652.
8. Borges M, Linnoila RI, van de Velde HJ etal. An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature 1997; 386: 852-855.
9. Jiang SX, Kameya T, Asamura H etal. hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod Pathol 2004; 17: 222-229.
10. Hiroshima K, Iyoda A, Shida T etal. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: A morphological, immunohistochemical, and molecular analysis. Mod Pathol 2006; 19: 1358-1368.
11. Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res 2005; 65: 10680-10685.
12. Osada H, Tomida S, Yatabe Y etal. Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancers. Cancer Res 2008; 68: 1647-1655.
13. Yazawa T, Ito T, Kamma H etal. Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma. Am J Pathol 2002; 161: 291-300.
14. Sutherland KD, Berns A. Cell of origin of lung cancer. Mol Oncol 2010; 4: 397-403.
15. Park KS, Liang MC, Raiser DM etal. Characterization of the cell of origin for small cell lung cancer. Cell Cycle 2011; 10: 2806-2815.
16. Calbo J, Meuwissen R, van Montfort E, van Tellingen O, Berns A. Genotype-phenotype relationships in a mouse model for human small-cell lung cancer. Cold Spring Harb Symp Quant Biol 2005; 70: 225-232.
17. Kashiwagi K, Ishii J, Sakaeda M etal. Differences of molecular expression mechanisms among neural cell adhesion molecule 1: Synaptophysin, and chromogranin A in lung cancer cells. Pathol Int 2012; 62: 232-245.
18. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 26: 663-676.
19. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Südhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010; 463: 1035-1041.
20. Ambasudhan R, Talantova M, Coleman R etal. Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. Cell Stem Cell 2011; 9: 113-118.
21. Lujan E, Chanda S, Ahlenius H, Südhof TC, Wernig M. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proc Natl Acad Sci USA 2012; 109: 2527-2532.
22. Ryan AK, Rosenfeld MG. POU domain family values: Flexibility, partnerships, and developmental codes. Genes Dev 1997; 11: 1207-1225.
23. He X, Treacy MN, Simmons DM, Ingraham HA, Swanson LW, Rosenfeld MG. Expression of a large family of POU-domain regulatory genes in mammalian brain development. Nature 1989; 340: 35-41.
24. Wegner M, Drolet DW, Rosenfeld MG. POU-domain proteins: Structure and function of developmental regulators. Curr Opin Cell Biol 1993; 5: 488-498.
25. Gerrero MR, McEvilly RJ, Turner E etal. Brn-3.0: A POU-domain protein expressed in the sensory, immune, and endocrine systems that functions on elements distinct from known octamer motifs. Proc Natl Acad Sci USA 1993; 90: 10841-10845.
26. Dominguez MH, Ayoub AE, Rakic P. POU-III transcription factors (Brn1, Brn2, and Oct6) influence neurogenesis, molecular identity, and migratory destination of upper-layer cells of the cerebral cortex. Cereb Cortex 2013; doi:10.1093/cercor/bhs252.
27. Phippard D, Lu L, Lee D, Saunders JC, Crenshaw EB III. Targeted mutagenesis of the POU-domain gene Brn4/Pou3f4 causes developmental defects in the inner ear. J Neurosci 1999; 19: 5980-5989.
28. Badea TC, Williams J, Smallwood P, Shi M, Motajo O, Nathans J. Combinatorial expression of Brn3 transcription factors in somatosensory neurons: Genetic and morphologic analysis. J Neurosci 2012; 32: 995-1007.
29. Nakai S, Kawano H, Yudate T etal. The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. Genes Dev 1995; 9: 3109-3121.
30. Schonemann MD, Ryan AK, McEvilly RJ etal. Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2. Genes Dev 1995; 9: 3122-3135.
31. Alvarez-Bolado G, Rosenfeld MG, Swanson LW. Model of forebrain regionalization based on spatiotemporal patterns of POU-III homeobox gene expression, birthdates, and morphological features. J Comp Neurol 1995; 355: 237-295.
32. Cook AL, Sturm RA. POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis. Pigment Cell Melanoma Res 2008; 2: 611-626.
33. Schreiber E, Himmelmann A, Malipiero U, Tobler A, Stahel R, Fontana A. Human small cell lung cancer expresses the octamer DNA-binding and nervous system-specific transcription factor N-Oct 3 (brain-2). Cancer Res 1992; 52: 6121-6124.
34. Eyden B, Pandit D, Banerjee SS. Malignant melanoma with neuroendocrine differentiation: Clinical, histological, immunohistochemical and ultrastructural features of three cases. Histopathology 2005; 47: 402-409.
35. Yazawa T, Sato H, Shimoyamada H etal. Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. Am J Pathol 2009; 175: 976-987.
36. Sato H, Yazawa T, Suzuki T etal. Growth regulation via insulin-like growth factor binding protein-4 and -2 in association with mutant K-ras in lung epithelia. Am J Pathol 2006; 169: 1550-1566.
37. Shimoyamada H, Yazawa T, Sato H etal. Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells. Am J Pathol 2010; 177: 70-83.
38. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet 1998; 352: 799-805.
39. Yao JC, Hassan M, Phan A etal. One hundred years after 'carcinoid': Epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
40. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995; 75 (1 Suppl): 191-202.
41. Travis WD. Lung tumours with neuroendocrine differentiation. Eur J Cancer 2009; 45 (Suppl 1): 251-266.
42. Travis WB. The concept of pulmonary neuroendocrine tumours. In: Travis WB, Brambilla E, Muller-Hermelink HK, Harris CC, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung: Pleura, Thymus, and Heart. Lyon: IARC Press, 2004; 19-20.
43. Sorhang S, Steinshamn S, Haaverstad R, Nordrum IS, Martinsen TC, Waldum HL. Expression of neuroendocrine markers in non-small cell lung cancer. APMIS 2007; 115: 152-163.
44. Ionescu DN, Treaba D, Gilks CB etal. Nonsmall cell lung carcinoma with neuroendocrine differentiation - an entity of no clinical or prognostic significance. Am J Surg Pathol 2007; 31: 26-32.
45. Thomson JA, Murphy K, Baker E etal. The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. Oncogene 1995; 11: 691-700.
46. Cook AL, Sturm RA. POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis. Pigment Cell Melanoma Res 2008; 21: 611-626.
47. Goodall J, Wellbrock C, Dexter TJ, Roberts K, Marais R, Goding CR. The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol 2004; 24: 2923-2931.
48. Cobrinik D, Francis RO, Abramson DH, Lee TC. Rb induces a proliferative arrest and curtails Brn-2 expression in retinoblastoma cells. Mol Cancer 2006; doi: 10.1186/1476-4598-5-72.
49. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001; 28 (2 Suppl 4): 3-13.